OTTAWA — The use of oral rather than intravenous (IV) steroids to respond to relapses in patients with relapsing-remitting multiple sclerosis (RRMS) is growing, a study suggested. The data, which were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results